Summary
This 10-Q filing for Alnylam Pharmaceuticals, Inc. (ALNY) for the period ending March 31, 2010, primarily details unaudited financial statements and management's discussion of financial condition and results of operations. Investors should note that as a development-stage biopharmaceutical company, Alnylam's financial statements reflect significant operating losses and reliance on financing activities, which is typical for its industry. The company is focused on the development of RNA interference (RNAi) therapeutics.
Financial Highlights
21 data pointsBeta
Financial Statements
Beta
| Revenue | $24.56M |
| R&D Expenses | $24.70M |
| Operating Expenses | $35.87M |
| Operating Income | -$11.31M |
| Net Income | -$12.32M |
Key Highlights
- 1The report contains unaudited condensed consolidated financial statements for the three months ended March 31, 2010, and 2009.
- 2Key financial statements presented include the Balance Sheets, Statements of Operations and Comprehensive Loss, and Statements of Cash Flows.
- 3Management's Discussion and Analysis (MD&A) provides insights into the company's financial condition and operational results.
- 4The filing includes disclosures regarding market risk, controls and procedures, and risk factors.
- 5Legal proceedings and exhibits are also part of the report, offering a comprehensive view of the company's status.
- 6As a development-stage company, expect continued investment in research and development, leading to operating losses.
Frequently Asked Questions
Alnylam Pharmaceuticals, Inc. is focused on the development of RNA interference (RNAi) therapeutics, a novel class of medicines designed to potentially treat a wide range of diseases.
As of March 31, 2010, Alnylam is likely continuing its development-stage operations, which typically involves significant operating losses. Investors should review the Statements of Operations and Cash Flows for details on revenue, expenses, and cash burn. The company would likely be relying on financing activities to fund its operations.
Investors should carefully review 'Item 1A. Risk Factors' which outlines potential challenges and uncertainties faced by Alnylam. These typically include risks related to drug development, clinical trials, regulatory approvals, intellectual property, competition, and the company's ability to secure future funding.
Detailed financial performance information for the three months ended March 31, 2010, and 2009, can be found in the 'CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS' and the accompanying notes within 'ITEM 1. FINANCIAL STATEMENTS'.